Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Olszewski

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood Advances|August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional seriesNarendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Advances|May 12, 2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyAdam S Zayac, Daniel J Landsburg, Mitchell E Hughes, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances|February 23, 2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphomaJuan Pablo Alderuccio, Luca Arcaini, Marcus P Watkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.
Blood Advances|August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional seriesNarendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia & Lymphoma|April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patientsSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Advances|May 12, 2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyAdam S Zayac, Daniel J Landsburg, Mitchell E Hughes, et al.
Pageof 29